Application of Tetrameric Recombinant Human Butyrylcholinesterase as a Biopharmaceutical for Amelioration of Symptoms of Acute Organophosphate Poisoning by Terekhov S. et al.
430
0007­-4888/17/16340430­­©­2017­­Springer­Science+Business­Media­New­York
Application of Tetrameric Recombinant Human 
Butyrylcholinesterase as a Biopharmaceutical for Amelioration 
of Symptoms of Acute Organophosphate Poisoning
S. S. Terekhov1, V. A. Palikov2, Y. A. Palikova2, I. A. Dyachenko2,  
O. G. Shamborant1, I. V. Smirnov1, P. Masson3, and A. G. Gabibov1
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 163, No. 4, pp. 425-430, April, 2016
Original article submitted November 30, 2016
We present a procedure for optimizing the expression of recombinant tetrameric butyryl-
cholinesterase that enables large-scale production with the yield >30 mg/liter (>90 mg/roller 
bottle). Intravenous injection of the preparation significantly increased survival and decreased 
the severity of symptoms of poisoning with paraoxon, an organophosphorus toxin.
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Acute organophosphorus (OP) poisoning is one of the 
most frequent causes of mortality related to chemical 
poisoning (260,000 deaths annually) [5]. Most victims 
are residents of the Western Pacific Region, where OP 
poisoning accounts more 50% of suicide attempts. 
Accident OP poisonings associated with improper 
handling of pesticides during agricultural activities 
are also frequent. Numerous cases of OP application 
during military operations and terrorist acts also pose 
a serious threat and necessitate the development of 
highly effective methods for treating OP poisoning.
Modern therapy of OP poisoning is based on com-
bined use of muscarinic receptor antagonist (atropine) 
and acetylcholinesterase reactivator (pralidoxime or 
obidoxime) [2]. Although this treatment is effective 
in some types of OP poisoning, it shows no positive 
effect in case of pesticide poisoning and does not pre-
vent irreversible brain damage [3]. In this context, 
biological antidotes (bioscavengers) are of great inter-
est, because they can irreversibly inactivate OP before 
they attack their biological target, acetylcholinesterase 
[7], and protect the nerve cells from damage by OP.
Human butyrylcholinesterase (hBCHE) is a natu-
ral bioscavenger in OP poisoning [14] and can inacti-
vate a wide spectrum of OP [11]. The use of hBCHE 
improves survival rate during poisoning with war-
fare agents of type V [4,8] (>8LD50 in the case of 
VX gases) and type G [4,10] (> 5.5LD50 in case of 
soman), as well as with pesticides [4,9]. Moreover, 
the use of hBCHE allows preventing long-term side 
adverse of OP poisoning, including irreversible brain 
damage [12].
Despite unique therapeutic indices of hBCHE-
based biopharmaceutical, its large-scale production is 
limited, as it needs to be isolated from human blood 
plasma, which makes it extremely expensive and un-
safe because of the risk of viral contamination. The 
possibility of large-scale production of recombinant 
hBCHE was previously demonstrated for plants [4] 
and transgenic animals [6], but hBCHE in these sys-
tems is produced as a mixture of monomers and dimers 
characterized by extremely rapid excretion (τ1/2≈2 min) 
from circulation, unlike their natural tetrameric form.
Using an alternative approach to produce hBCHE 
in CHO cells and genetic constructs carrying hBCHE 
gene and a sequence encoding native tetramerization 
peptide, we achieved a high level of production of ex-
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